Levetiracetam Price Trend

Levetiracetam Price Trend, Index and Forecast

Track the latest insights on levetiracetam price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.

Levetiracetam Prices Outlook Q2 2025

• USA: US$ 36,500/MT
• China: US$ 26,670/MT
• India: US$ 34,118/MT
• Germany: US$ 42,560/MT
• France: US$ 44,800/MT

Levetiracetam Price Chart

Get real-time access to monthly/quaterly/yearly prices, Request Sample

During the second quarter of 2025, levetiracetam prices in the USA reached 36,500 USD/MT in June. Levetiracetam prices in the United States remained largely stable during the second quarter of 2025, supported by consistent demand from hospitals, clinics, and outpatient neurology practices. Mild fluctuations were observed due to variable costs of pharmaceutical-grade raw materials and rising energy expenses. Regulatory compliance and quality assurance requirements contributed to overall production costs. Despite occasional logistical bottlenecks, the supply chain remained mostly undisrupted. Market sentiment stayed firm, with levetiracetam prices aligning closely with input costs and stable therapeutic demand, particularly in the treatment of epilepsy and seizure-related disorders.

During the second quarter of 2025, levetiracetam prices in China reached 26,670 USD/MT in June. Levetiracetam prices in China exhibited mild fluctuations, primarily influenced by variable costs of active pharmaceutical ingredients and rising energy prices. Domestic production remained stable, supported by strong local manufacturing infrastructure and consistent demand from hospitals and neurology clinics. However, occasional supply chain disruptions and stricter regulatory controls contributed to modest price volatility. Export conditions and currency fluctuations also played a role in shaping cost dynamics. Despite these pressures, overall market sentiment remained stable, with prices closely aligned to input cost trends and steady therapeutic utilization.

During the second quarter of 2025, levetiracetam prices in India reached 34,118 USD/MT in June. Levetiracetam prices in India remained relatively stable throughout, supported by a strong domestic production base and consistent demand in both the public and private healthcare sectors. Input cost fluctuations, especially for raw materials and energy, introduced minor pricing variability. Regulatory compliance and quality standards added to production overheads, while exports experienced modest logistical delays. Despite these factors, the pricing environment reflected a well-balanced market, with manufacturers adjusting prices in line with material costs and maintaining a steady supply to meet therapeutic demand.

During the second quarter of 2025, levetiracetam prices in Germany reached 42,560 USD/MT in June. Levetiracetam prices showed moderate fluctuations, primarily influenced by variable energy tariffs and compliance-related production expenses. Demand from hospitals and clinics remained consistent, backed by levetiracetam’s established use in epilepsy treatment. While the domestic supply chain remained resilient, import dynamics and currency fluctuations had a slight impact on procurement costs. Environmental and pharmaceutical regulations continued to impact manufacturing margins. Overall, pricing remained firm, with adjustments reflecting changes in input costs and steady clinical utilization.

During the second quarter of 2025, levetiracetam prices in France reached 44,800 USD/MT in June. Levetiracetam prices in France remained largely stable, with slight variations attributed to changes in energy and operational costs. The country’s national health system ensured consistent demand, particularly in neurology departments. Local manufacturers maintained a reliable supply, though minor delays in raw material sourcing introduced temporary pressures. Regulatory obligations related to packaging, safety, and sustainability added to production expenses. Despite these factors, the market-maintained equilibrium, with prices generally aligned to supply chain conditions and steady prescription volumes.

Regional Coverage

The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing the Levetiracetam prices.

Global Levetiracetam Price Trend

The report offers a holistic view of the global Levetiracetam pricing trends in the form of Levetiracetam price charts, reflecting the worldwide interplay of supply-demand balances, international trade policies, and overarching economic factors that shape the market on a macro level. This comprehensive analysis not only highlights current price levels but also provides insights into historical price of Levetiracetam, enabling stakeholders to understand past fluctuations and their underlying causes. The report also delves into price forecast models, projecting future price movements based on a variety of indicators such as expected changes in supply chain dynamics, anticipated policy shifts, and emerging market trends. By examining these factors, the report equips industry participants with the necessary tools to make informed strategic decisions, manage risks, and capitalize on market opportunities. Furthermore, it includes a detailed Levetiracetam demand analysis, breaking down regional variations and identifying key drivers specific to each geographic market, thus offering a nuanced understanding of the global pricing landscape.

Europe Levetiracetam Price Trend

Q2 2025:

In Europe, levetiracetam prices showed mild fluctuations, primarily influenced by varying energy and production costs across the region. Demand remained steady from both public healthcare systems and private providers, driven by its established role in epilepsy management. Countries such as Germany, France, and Italy maintained consistent usage, while their supply chains operated efficiently despite minor logistical challenges. Overall, the pricing environment remained stable, with levetiracetam prices aligning with input costs and sustained therapeutic demand across major European pharmaceutical markets.

This analysis can be extended to include detailed levetiracetam price information for a comprehensive list of countries.

North America Levetiracetam Price Trend

Q2 2025:

In North America, levetiracetam prices remained steady, supported by stable demand from hospitals and outpatient neurology clinics. The region experienced consistent consumption across the U.S. and Canada, driven by its widespread use in seizure management. Minor pricing fluctuations were attributed to changes in production input costs and regulatory compliance expenses. Supply chains remained largely undisrupted, with generic manufacturers maintaining strong distribution networks. Overall, levetiracetam pricing reflected a balanced market, with rates closely aligned to manufacturing trends and consistent therapeutic demand throughout the quarter.

Specific levetiracetam historical data within the United States and Canada can also be provided.

Middle East and Africa Levetiracetam Price Trend

Q2 2025:

The report explores the levetiracetam trends and levetiracetam price chart in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices. 

In addition to region-wise data, information on levetiracetam prices for countries can also be provided.

Asia Pacific Levetiracetam Price Trend

Q2 2025:

In the Asia Pacific region, levetiracetam prices remained largely stable during the second quarter of 2025, supported by consistent demand from neurological care segments and robust generic manufacturing across countries such as India and China. Moderate fluctuations were observed due to variable raw material and energy costs, as well as currency shifts impacting export margins. Regional pharmaceutical companies maintained steady production and supply, ensuring minimal disruptions to the market. Overall, the pricing environment reflected balanced supply-demand conditions, with levetiracetam prices aligning closely with input cost trends and sustained therapeutic use across major healthcare systems.

This levetiracetam price analysis can be expanded to include a comprehensive list of countries within the region.

Latin America Levetiracetam Price Trend

Q2 2025:

Latin America's levetiracetam market is predominantly influenced by its rich natural reserves, particularly in countries like Chile and Brazil. However, political instability and inconsistent regulatory frameworks can lead to significant volatility in levetiracetam prices. Infrastructure challenges and logistical inefficiencies often impact the supply chain, affecting the region's ability to meet international demand consistently. Moreover, levetiracetam index, economic fluctuations, and currency devaluation are critical factors that need to be considered when analyzing levetiracetam pricing trends in this region.

This comprehensive review can be extended to include specific countries within the region.

Levetiracetam Price Trend, Market Analysis, and News

IMARC's latest publication, “Levetiracetam Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2025 Edition,” presents a detailed examination of the levetiracetam market, providing insights into both global and regional trends that are shaping prices. This report delves into the spot price of levetiracetam at major ports and analyzes the composition of prices, including FOB and CIF terms. It also presents a detailed levetiracetam price trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors affecting levetiracetam pricing, such as the dynamics of supply and demand, geopolitical influences, and sector-specific developments, are thoroughly explored. This comprehensive report helps stakeholders stay informed with the latest market news, regulatory updates, and technological progress, facilitating informed strategic decision-making and forecasting.

Levetiracetam Industry Analysis

The global levetiracetam market size reached US$ 1.59 Billion in 2024. By 2033, IMARC Group expects the market to reach US$ 3.55 Billion, at a projected CAGR of 9.13% during ​2025-2033​.

• The levetiracetam industry continues to experience steady growth, driven by its expanding role in epilepsy management and favorable safety profile. As an antiepileptic drug, levetiracetam is widely used to treat partial-onset, myoclonic, and generalized tonic-colonic seizures. Its mechanism of action, distinct from other AEDs, and its relatively low potential for drug interactions have made it a preferred choice among neurologists. Increased awareness and diagnosis of epilepsy across both developed and developing countries have contributed to its growing demand in recent years.
• The global market has seen a rise in the availability of both branded and generic versions of levetiracetam, which has improved accessibility, particularly in low- and middle-income regions. Regulatory approvals for newer formulations—such as intravenous injections, extended-release tablets, and pediatric oral solutions—have broadened their clinical applicability. Hospitals and outpatient settings increasingly prefer levetiracetam for acute seizure control, especially when oral therapy is not feasible, due to its rapid onset and tolerability. Moreover, healthcare providers are opting for it in elderly and pediatric populations due to its manageable side-effect profile.
• In terms of industry dynamics, pharmaceutical companies are investing in advanced manufacturing and packaging innovations to enhance product stability, shelf life, and administration convenience. Collaborations between generic manufacturers and healthcare institutions have strengthened distribution channels, ensuring wider market penetration. Furthermore, the growing prevalence of neurological disorders, driven by increased healthcare spending and enhanced diagnostic infrastructure, is expected to sustain long-term demand. As research into epilepsy and seizure disorders continues, levetiracetam remains a cornerstone therapy, supported by its proven efficacy and compatibility with combination treatments. Overall, the market outlook for levetiracetam remains robust, with continued product diversification and geographical expansion reinforcing its global footprint.

Levetiracetam News

The report covers the latest developments, updates, and trends impacting the global levetiracetam industry, providing stakeholders with timely and relevant information. This segment covers a wide array of news items, including the inauguration of new production facilities, advancements in levetiracetam production technologies, strategic market expansions by key industry players, and significant mergers and acquisitions that impact the levetiracetam price trend.

Latest developments in the Levetiracetam industry:

• May 2024: B. Braun Medical Inc., a company pioneering in smart infusion therapy and pain management, has launched its new Levetiracetam in Sodium Chloride Injection product line, marking an expansion of its offerings in the anticonvulsant category. The injectable solution is available in three dosage strengths: 500 mg/100 mL, 1,000 mg/100 mL, and 1,500 mg/100 mL.

Product Description

Levetiracetam is an antiepileptic drug used to treat various types of seizures in individuals with epilepsy. It is commonly prescribed for partial-onset seizures, myoclonic seizures, and generalized tonic-colonic seizures in both adults and children. Levetiracetam works by modulating neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing brain electrical activity and reducing seizure frequency. It is available in multiple formulations, including oral tablets, extended-release tablets, oral solution, and intravenous injection, allowing for flexible administration based on patient needs.

Known for its favorable safety profile, levetiracetam is generally well-tolerated, with common side effects including dizziness, fatigue, and mood changes. It is often preferred for its minimal drug interactions and ease of dose adjustment. Due to its efficacy and tolerability, levetiracetam has become a widely used first-line therapy in seizure management and is frequently included in long-term epilepsy treatment plans.

Report Coverage

Key Benefits for Stakeholders:

• IMARC’s report presents a detailed analysis of levetiracetam pricing, covering global and regional trends, spot prices at key ports, and a breakdown of FOB and CIF prices.
• The study examines factors affecting levetiracetam price trend, including input costs, supply-demand shifts, and geopolitical impacts, offering insights for informed decision-making.
• The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
• IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The levetiracetam price charts ensure our clients remain at the forefront of the industry.